Need immediate assistance? Call 1-518-730-0559 (Us-Canada Toll Free) or Contact Us


U.S. Bacterial Conjunctivitis Drugs Market to Witness Decline due to Reducing Demand for Branded Drugs

Blog Description

Bacterial conjunctivitis is one of the most common eye problem across the globe and is caused by several bacterial strains, including staphylococci, streptococci, gonococci, and chlamydial organisms. Most strains of bacterial conjunctivitis are acute, self-limited, and not a key cause of morbidity. The U.S. market for bacterial conjunctivitis drugs is becoming very crowded, due to which the profit margins earned by key players initially are estimated to face a setback in the near future. The increasing fragmentation in the U.S. bacterial conjunctivitis drugs market is further encouraging an intense competitive scenario in forthcoming years. 

Browse Full U.S. Bacterial Conjunctivitis Drugs Market Report with TOC:

According to the research study, the bacterial conjunctivitis drugs market in the U.S. is estimated to decline in valuation in the coming few years. In 2013, the bacterial conjunctivitis drugs market in the U.S. stood at US$473.3 mn. It is estimated to witness a downward trajectory and reach a value of US$439.8 mn by 2024. In the next few years, the U.S. market is estimated to witness the adverse effects of patent expiry as some of the leading brands of bacterial conjunctivitis drugs are anticipated to lose their market share soon.

Key Players to Witness Huge Losses due to Rise of Generics in Recent Years

The increasing genericization of antibacterial drugs has affected the demand for branded drugs considerably. The generic forms of patented formulations, which bear similar efficiency, are available at cheap rates in the bacterial conjunctivitis drugs market. This trend is estimated to hamper the growth of the overall market in the near future. The rise of generic drugs in the market has resulted in huge losses for leading ophthalmic drug manufacturers, further restricting the growth of the market.

In 2013, the three leading drug manufacturers of bacterial conjunctivitis drugs in the U.S. market together held a 57% share in the overall market. Many new players participating in the market hold robust research and development capabilities; however, they often lack financial assets. The key players engaged in this market are focusing on mergers and acquisitions in order to strengthen their position in the market by providing financial support to promising research lines developed by new players and gain a competitive advantage in the next few years. 

Rising Efficiency of Fluoroquinolones to Augment Growth of Bacterial Conjunctivitis Drugs Market in U.S.

The bacterial conjunctivitis drugs market in the U.S. can be segmented on the basis of drug class into aminoglycosides, macrolides, fluoroquinolones, and others. Among these drug classes, the fluoroquinolones segment is anticipated to experience a steady rise in the next few years. The rising efficiency of these drugs is considered a key factor anticipated to bolster the growth of the segment in the coming few years.

Browse the full Press Release of U.S. Bacterial Conjunctivitis Drugs Market at

Many of the key players in the U.S. bacterial conjunctivitis drugs market are emphasizing on introducing herbal medicines, as several consumers are inclined towards herbal medicines at present. Some of the prominent players in the market are Novartis AG, F. Hoffmann-La Roche Ltd., Santen Pharmaceutical Co. Ltd., Merck & Co. Inc., Actavis Plc, Valeant Pharmaceuticals Intl. Inc., Perrigo Com. Plc., Akorn Inc., Pfizer Inc., and Bayer AG.